Press Releases.
Media Contact: Mingjie Xie, M.Sc., M.B.A., CEO, +1 (519) 593-2260, pr@rapidnovor.com
Mar 16, 2023 – Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US
Mar 6, 2023 – Bruker Launches de novo Sequencing for Immunopeptidomics, Library-Free dia-PASEF, Mass Dynamics Knowledge Visualization
July 11, 2022 – Alpaca Serum Antibodies Decoded with Rapid Novor’s De Novo Protein Sequencing Technology
May 27, 2021 – Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics
July 28, 2020 – Kitchener Biotech Rapid Novor Raised $5M USD to Decode Immune System
October 2, 2019 – Next Generation Protein Sequencing Company Rapid Novor Enters into New Phase of Growth
August 16, 2018 – Rapid Novor Inc Expands Their Proteomics Lab and Welcomes the 3rd Mass Spectrometer
May 14, 2018 – Canadian Mass Spectrometry Veteran, Paul Taylor, Joins Rapid Novor Inc.
March 1, 2018 – Dr. Thierry Le Bihan Joins Rapid Novor Inc. to Further Advance Antibody Protein Sequencing Technologies
February 13, 2018 – Rapid Novor Inc Announces Residency in JLABS @ Toronto
January 24, 2018 – Rapid Novor Inc. Launches REmAb™ Antibody Protein Sequencing Services on Science Exchange
August 22, 2017 – Next-Generation Protein Sequencing – CEOCFO Magazine Interview with Rapid Novor Inc
July 19, 2017 – Rapid Novor Inc Opens Research Lab in Kitchener to Develop the Next-Generation Protein Sequencing Technology
In The News.
July 28, 2020 – By Beth Gallagher, University of Waterloo
A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses like cancer and COVID-19, is expanding operations with the help of a $5-million USD investment.
Waterloo tech profiles antibodies in blood of COVID-19 patients
Aug 20, 2018 – By Maggie Lynch, Outsourcing-Pharma.com
Rapid Novor has expanded its proteomics lab with the addition of a third mass spectrometer – enabling the company to take on more projects, says CEO.
Rapid Novor expands proteomics lab with third mass spectrometer
Mar 23, 2018 – HiTechCanada – Interview conducted by Huayu Niu, HiTechCanada.
HiTech Face to Face (Language: Mandarin)
Jan 9, 2018 – News-Medical.Net – Insights from industry – An interview with Mingjie Xie, conducted by James Ives, MPsych
Deciphering Antibodies with Next-Generation Protein Sequencing Technology
Nov 15, 2017 – Ontario Genomics
Ontario Genomics has closed an investment in Rapid Novor, a Kitchener-Waterloo based biotech company that provides rapid, accurate, de novo protein sequencing services across Canada and internationally.
Ontario Genomics invests in antibody protein sequencing company Rapid Novor
Aug 21, 2017 – CEOCFO Magazine – Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – August 21, 2017
CEOCFO Magazine Interviews Rapid Novor Inc CEO, Mingjie Xie
Jul 19, 2017 – Waterloo Region Record
Rapid Novor, a startup that went through the Accelerator Centre in the David Johnston Research and Technology Park, is now based at 44 Gaukel St. in downtown Kitchener. Specializing in what’s called protein sequencing, the six-member team is among a small, but growing, number of biotech startups in the region.
Big science out of a small lab
Talk to Our Scientists.
We Have Sequenced 7000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics